权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

NOVEL STRATEGIES TO IMPROVE LIVER CANCER SURVEILLANCE UPTAKE AND EARLY DETECTION

提高肝癌监测率和早期检测率的新策略

基本信息

批准号：
10457301
负责人：
ANNA S.F. LOK
金额：
$ 66.54万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-13 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10457301
关键词：
Abdomen Address Algorithms Area Benign Binding Biological Markers Biological Specimen Banks Center for Translational Science Activities Cirrhosis Clinical Clinical Research Computerized Medical Record Contrast Media Data Detection Diagnosis Early Diagnosis Engineering Enrollment Funding GPC3 gene Goals Health Personnel Hepatitis C Image Incidence Information Technology Intestinal Diseases Label Laboratories Lesion Liver Liver diseases Machine Learning Magnetic Resonance Imaging Malignant - descriptor Malignant Epithelial Cell Malignant Neoplasms Malignant neoplasm of liver Measurement Medical Imaging Methods Modeling Nodule Organ Pancreatic Diseases Patients Peptides Populations at Risk Primary Malignant Neoplasm of Liver Primary carcinoma of the liver cells Prospective Studies Provider Radiology Specialty Research Resources Risk Scanning Screening for Hepatocellular Cancer Sensitivity and Specificity Serum Specialist Specific qualifier value Specimen Surface System Testing Time Tissues United States United States National Institutes of Health Work X-Ray Computed Tomography accurate diagnosis baby boomer base data repository diagnostic accuracy diagnostic tool diagnostic value experience follow-up image processing imaging biomarker imaging study improved novel novel strategies patient screening patient stratification patient-level barriers predictive modeling predictive tools radiomics repository response risk stratification sample collection screening statistics surveillance imaging surveillance strategy ultrasound uptake

项目摘要

ABSTRACT This proposal is submitted in response to RFA-CA-17-025. Hepatocellular carcinoma (HCC) is the most common primary liver cancer and one of the few cancers with increasing incidence in the United States. Survival of patients with HCC is poor because most patients are diagnosed at late stages when treatment options are limited. HCC surveillance can detect cancers early and improve survival but it is inconsistently implemented. Not all liver nodules detected on surveillance imaging are malignant, these indeterminate nodules require follow up imaging to determine if they are HCC. This proposal assembles a team of specialists with complementary expertise in liver diseases, liver cancer, radiology, engineering, statistics, and information technology. The goals are to: (1) Improve HCC surveillance uptake in patients with cirrhosis by leveraging electronic medical records to remind healthcare providers and patients when they are due for screening tests; (2) Leverage analytic morphomics and machine learning to increase the detectability of HCC at an early stage; and (3) Increase detectability of HCC at an early stage using tagged HCC-specific peptides. We have worked closely together for many years and have participated/led many NIH funded clinical research networks. We have expertise and experience to carry out the proposed studies and will collaborate with other centers in the Liver Center Network to validate the methods/models we develop. We will also enroll patients with cirrhosis and collect data and specimens and provide access to existing well characterized data and specimen repositories that include both prevalent and incident HCC for Trans-Network studies. We are confident we will be able to contribute to this Liver Cancer Network and to early detection of HCC in multiple ways.

摘要本提案是根据RFA-CA-17-025提交的。肝细胞癌（HCC）是最常见的常见的原发性肝癌，也是美国发病率上升的少数癌症之一。 HCC患者的生存率很低，因为大多数患者在治疗时被诊断为晚期。选择有限。HCC监测可以早期发现癌症并提高生存率，但这并不一致。切实贯彻并不是所有在监测成像上检测到的肝结节都是恶性的，这些不确定的结节需要随访成像以确定它们是否是HCC。这个建议召集了一个专家小组在肝病、肝癌、放射学、工程学、统计学和信息学方面具有互补的专业知识技术.目标是：（1）通过利用肝硬化患者的肝细胞癌监测，电子医疗记录，以提醒医疗保健提供者和患者，当他们由于筛选测试; (2)利用分析形态学和机器学习来提高HCC的早期检测能力; 和（3）使用标记的HCC特异性肽在早期阶段增加HCC的可检测性。我们一直多年来一直密切合作，并参与/领导了许多NIH资助的临床研究网络。我们具有开展拟议研究的专业知识和经验，并将与世界其他中心合作，肝脏中心网络来验证我们开发的方法/模型。我们还将招募肝硬化患者收集数据和样本，并提供对现有良好表征的数据和样本的访问包括用于跨网络研究的流行和偶发HCC的存储库。我们有信心能够为这个肝癌网络做出贡献，并以多种方式早期发现HCC。